Global Health: What’s Ahead for 2022: Antimicrobial Resistance
Antimicrobial resistance (AMR), which is making a growing range of antibiotics ineffective, is anincreasingly critical problem. Driven la...
Antimicrobial resistance (AMR), which is making a growing range of antibiotics ineffective, is anincreasingly critical problem. Driven la...
It’s fair to say that the current state of health financing is mixed. On the one hand, outside of pandemic-related funding, public financ...
Nothing in recent years has focused the world’s attention on the development, use, and efficacy of vaccines more than COVID-19. Through e...
Comparing the road ahead for mandatory corporate ESG disclosures in the two markets.
Moving toward uniform environmental reporting standards to catalyze corporate performance.
Five things we will be looking for from G20 leaders, health and finance officials.
What business and organizations need to know about this critical moment for global engagement on climate resiliency.
Key intellectual property issues to be addressed at the World Trade Organization, amid the ongoing COVID-19 response.
CMI insights on where business and civil society can engage global policymakers on climate change.
Analysis for The National Bureau of Asian Research on trade, data governance, and cross-border data flows in the Asia-Pacific.